Azathioprine in the prevention of anti-infliximab antibody formation: A pilot dose-finding study

被引：0
|
作者：
Kojecky, V. [1 ,2 ]
Wasserbauer, M. [3 ,4 ]
Keil, R. [3 ,4 ]
机构：
[1] Masaryk Univ, Fac Med, Brno, Czech Republic
[2] Bata Reg Hosp, Dept Internal Med, Zlin, Czech Republic
[3] Charles Univ Prague, Prague, Czech Republic
[4] Motol Univ Hosp, Dept Internal Med, Prague, Czech Republic
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P599
引用
收藏
页码：I533 / I533
页数：1
相关论文
共 50 条
  • [31] Dose-finding study of oral metopimazine
    Jørn Herrstedt
    Tine Sigsgaard
    Helle R. Angelo
    Jens P. Kampmann
    Mogens Hansen
    Supportive Care in Cancer, 1997, 5 : 38 - 43
  • [32] Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays
    Van Stappen, Thomas
    Brouwers, Els
    Tops, Sophie
    Geukens, Nick
    Vermeire, Severine
    Declerck, Paul J.
    Gils, Ann
    THERAPEUTIC DRUG MONITORING, 2015, 37 (04) : 479 - 485
  • [33] Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit
    Mihika B. Dave
    Alpa J. Dherai
    Devendra C. Desai
    Bhamini G. Keny
    Dhanashri N. Shetty
    Satish Kulkarni
    Kiran Peddy
    Tester F. Ashavaid
    Indian Journal of Gastroenterology, 2020, 39 : 426 - 434
  • [34] TROUGH INFLIXIMAB LEVELS AND ANTI-INFLIXIMAB ANTIBODIES IN SPONDYLOARTHRITIS PATIENTS ON TREATMENT WITH LOW DOSE INFLIXIMAB: A SINGLE CENTRE CROSS-SECTIONAL STUDY
    Patil, A.
    Upadhyaya, S. K.
    Dawar, R.
    Vaishnav, B.
    Dadhaniya, N.
    Gupta, S. J.
    Handa, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1292 - 1292
  • [35] RISK FACTORS FOR ANTI-INFLIXIMAB ANTIBODY FORMATION: RESULTS FROM THE RANDOMISED CONTROLLED NOR-DRUM A TRIAL
    Brun, M. K.
    Goll, G. L.
    Jorgensen, K. K.
    Sexton, J.
    Gehin, J. E.
    Sandanger, O.
    Olsen, I.
    Klaasen, R. A.
    Warren, D. J.
    Mork, C.
    Kvien, T. K.
    Jahnsen, J.
    Bolstad, N.
    Haavardsholm, E. A.
    Syversen, S. W.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 185 - 185
  • [36] Trough serum infliximab level, anti-infliximab antibody status and response to infliximab maintenance treatment in inflammatory bowel disease (IBD)
    Kong, J. Y.
    Bundell, C. S.
    Pawlik, J.
    Hollingsworth, P. N.
    Forbes, G. M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 59 - 60
  • [37] Correction to: Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit
    Mihika B. Dave
    Alpa J. Dherai
    Devendra C. Desai
    Bhamini G. Keny
    Dhanashri N. Shetty
    Satish Kulkarni
    Kiran Peddi
    Tester F. Ashavaid
    Indian Journal of Gastroenterology, 2020, 39 : 629 - 629
  • [38] Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays
    Nice, Rachel
    Chanchlani, Neil
    Green, Harry
    Bewshea, Claire
    Ahmad, Tariq
    Goodhand, James R.
    McDonald, Timothy J.
    Perry, Mandy H.
    Kennedy, Nicholas A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (01) : 128 - 137
  • [39] Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease
    Steenholdt, Casper
    DANISH MEDICAL JOURNAL, 2013, 60 (04):
  • [40] Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
    Steenholdt, Casper
    Al-khalaf, Magid
    Brynskov, Jorn
    Bendtzen, Klaus
    Thomsen, Ole O.
    Ainsworth, Mark A.
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (12) : 2209 - 2217
12345